A study of 2 MMR vaccines in 9-12 month old infants.

ABSTRACT

The MMR vaccines licensed in Thailand, Triviraten and MMR II, were used in the present study in order to evaluating their immunogenicity and safety. The study was carried out at Paholpolpayuhasena Hospital during the period from January to August 1995. Subjects comprised 116 children which were randomly divided into 2 groups. The first group (no. = 58) received Triviraten and the second group (no. = 58) received MMR II. Seroconversion rate against measles, mumps and rubella were 94.83%, 79.31% and 96.55%, respectively in the Triviraten group, and were 84.48%, 91.38% and 98.28%, respectively in the MMR II group. The differences between the seroconversion rate of three vaccine components were of no statistical significant. The geometric mean titer for the measles (1,516.07 IU/L) and mumps (1,004.45 IU/L) strain in the MMR II group, however were significantly (P < 0.001) higher than the Triviraten group. Adverse reactions from vaccination were mild and showed no statistically significant difference between the two vaccines used.